Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies

被引：0
|
作者：
Rosario Pivonello
Giovanna Muscogiuri
Geoffrey Holder
Michaela Paul
Severine Sarp
Anastasia Lesogor
Pierre Jordaan
Johannes Eisinger
Annamaria Colao
机构：
[1] Dipartimento di Medicina Clinica e Chirurgia,
[2] Sezione di Endocrinologia,undefined
[3] Università Federico II di Napoli,undefined
[4] Novartis AG,undefined
来源：
Endocrine | 2018年 / 60卷
关键词：
Diabetic retinopathy; Octreotide; Long-term safety; Renal function; Hepatic function; Cardiac function;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：65 / 72
页数：7
相关论文
共 50 条
  • [21] A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects
    Cercato, C.
    Roizenblatt, V. A.
    Leanca, C. C.
    Segal, A.
    Lopes Filho, A. P.
    Mancini, M. C.
    Halpern, A.
    INTERNATIONAL JOURNAL OF OBESITY, 2009, 33 (08) : 857 - 865
  • [22] Effect of Brexpiprazole on Patient Functioning in Patients With Schizophrenia: Results From a Long-Term, Randomized, Double-Blind, Placebo-Controlled, Maintenance Study
    Therrien, Francois
    Weiss, Catherine
    Jin, Na
    Baker, Ross A.
    MacKenzie, Erin
    Meehan, Stine R.
    NEUROPSYCHOPHARMACOLOGY, 2017, 42 : S244 - S245
  • [23] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RISPERIDONE LONG-ACTING INJECTABLE IN RELAPSE PREVENTION IN PATIENTS WITH BIPOLAR I DISORDER
    Montgomery, S.
    Vieta, E.
    Sulaiman, A. H.
    Cordoba, R.
    Huberlant, B.
    Schreiner, A.
    Martinez, G.
    EUROPEAN PSYCHIATRY, 2010, 25
  • [24] Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study
    Barbare, Jean-Claude
    Bouche, Olivier
    Bonnetain, Franck
    Dahan, Laetitia
    Lombard-Bohas, Catherine
    Faroux, Roger
    Raoul, Jean-Luc
    Cattan, Stephane
    Lemoine, Alain
    Blanc, Jean-Frederic
    Bronowicki, Jean-Pierre
    Zarski, Jean-Pierre
    Cazorla, Sophie
    Gargot, Dany
    Thevenot, Thierry
    Diaz, Emmanuel
    Bastie, Anne
    Aparicio, Thomas
    Bedenne, Laurent
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (10) : 1788 - 1797
  • [25] SECUKINUMAB PROVIDES SUSTAINED REDUCTION IN FATIGUE IN PATIENTS WITH ANKYLOSING SPONDYLITIS THROUGH 3 YEARS: LONG-TERM RESULTS OF TWO RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDIES
    Kvien, T. K.
    Deodhar, A.
    Gossec, L.
    Conaghan, P. G.
    Strand, V.
    Ostergaard, M.
    Williams, N.
    Porter, B.
    Gandhi, K.
    Jugl, S.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S9 - S9
  • [26] Comparison of long-acting methylphenidate formulations in children with ADHD: Pooled analysis of 2 randomized, placebo-controlled studies
    Silva, RR
    Brams, M
    Childress, A
    Lopez, FA
    Pestreich, L
    Muniz, R
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2004, 14 (04) : 514 - 515
  • [27] Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study
    Unfer, V
    Casini, ML
    Costabile, L
    Mignosa, M
    Gerli, S
    Di Renzo, GC
    FERTILITY AND STERILITY, 2004, 82 (01) : 145 - 148
  • [28] ANTI-ISCHEMIC EFFECT OF NIFEDIPINE IN LONG-ACTING FORM - RESULTS OF A RANDOMIZED, DOUBLE-BLIND, CROSSOVER, PLACEBO-CONTROLLED, ACUTE STUDY
    BRUGMANN, U
    BLASINI, R
    RUDOLPH, W
    HERZ, 1983, 8 (04) : 206 - 210
  • [29] Efficacy of Milnacipran Following Long-Term Treatment of Fibromyalgia: Results from a Randomized, Double-Blind, Placebo-Controlled Discontinuation Study
    Clauw, Daniel
    Mease, Philip
    Ma, Yimin
    Baldecchi, Arlene
    Palmer, Robert
    Thacker, Kimberley
    Trugman, Joel
    NEUROLOGY, 2012, 78
  • [30] Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study
    Terra, JL
    Montgomery, SA
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1998, 13 (02) : 55 - 62
12345